The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares. Donald Trump's executive order changing 401 ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

The mini tender offer is for the purchase of up to 2 million American Depositary shares representing less than 0.045% of its ...